81206

BCR/ABL1 Gene Analysis, Major Breakpoint (p210) Qualitative or Quantitative

CPT code 81206 describes a molecular pathology procedure that analyzes the BCR/ABL1 (breakpoint cluster region/Abelson murine leukemia viral oncogene homolog 1) gene translocation, specifically focusing on the major breakpoint cluster region (M-bcr). This translocation, known as t(9;22)(q34;q11), results in the Philadelphia chromosome (Ph), which is the hallmark of Chronic Myeloid Leukemia (CML) and is also found in a subset of Acute Lymphoblastic Leukemia (ALL) cases. The major breakpoint typically leads to the production of the p210 fusion protein. The laboratory assay utilizes Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR) to detect and quantify the fusion transcripts (usually e13a2 or e14a2). This test is highly sensitive, capable of detecting one leukemic cell in a background of 100,000 normal cells. In clinical practice, 81206 is utilized for the initial diagnosis of Philadelphia chromosome-positive leukemias and, more critically, for the longitudinal monitoring of patients undergoing treatment with Tyrosine Kinase Inhibitors (TKIs). Quantitative results are frequently reported using the International Scale (IS), allowing for standardized comparisons of a patient's molecular response, such as Major Molecular Response (MMR). Monitoring transcript levels is essential for detecting Minimal Residual Disease (MRD) and identifying early molecular relapse before clinical symptoms or cytogenetic abnormalities reappear. The assay involves extracting RNA from peripheral blood or bone marrow, synthesizing cDNA, and amplifying the specific fusion sequence alongside a control gene (like ABL1 or GUSB) to calculate the ratio of BCR-ABL1 transcripts.

Clinical Indications

  • Confirmation of a suspected diagnosis of Chronic Myeloid Leukemia (CML)
  • Diagnosis of Philadelphia chromosome-positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
  • Monitoring of therapeutic response to Tyrosine Kinase Inhibitors (TKIs) such as imatinib, dasatinib, or nilotinib
  • Detection of Minimal Residual Disease (MRD) following chemotherapy or hematopoietic stem cell transplant
  • Surveillance for early molecular relapse in patients in clinical remission
  • Differentiation between CML and other myeloproliferative neoplasms
  • Determining the eligibility for treatment discontinuation in patients with sustained deep molecular response

Procedure Steps

  1. Collection of clinical specimen, typically 3-5 mL of peripheral blood in EDTA or 1-2 mL of bone marrow aspirate.
  2. Stabilization and extraction of total RNA from the nucleated cell fraction of the specimen.
  3. Quality assessment of the extracted RNA to ensure adequate concentration and integrity for downstream analysis.
  4. Reverse transcription of the RNA into complementary DNA (cDNA) using reverse transcriptase enzyme and primers.
  5. Real-time Quantitative Polymerase Chain Reaction (RT-qPCR) amplification using primers and fluorescent probes specific to the BCR-ABL1 major breakpoint (p210) fusion and a reference control gene (e.g., ABL1, GUSB, or BCR).
  6. Fluorescence monitoring during the amplification cycles to determine the cycle threshold (Ct) for both the target and control genes.
  7. Calculation of the ratio of BCR-ABL1 transcripts to control gene transcripts.
  8. Normalization of the results to the International Scale (IS) if applicable, based on laboratory-specific conversion factors.
  9. Interpretation of data to determine if the result is positive/negative (qualitative) and the precise molecular burden (quantitative).

Coding Guidelines

  • Report 81206 specifically for the major breakpoint (p210) fusion transcript; do not use this code for the minor (p190) or micro (p230) breakpoints.
  • For BCR/ABL1 minor breakpoint (p190) analysis, see CPT code 81207.
  • For BCR/ABL1 micro breakpoint (p230) analysis, see CPT code 81208.
  • The code 81206 includes both qualitative (detection) and quantitative (amount) analysis; do not report both 81206 and a general qualitative code for the same breakpoint in the same session.
  • If testing for kinase domain mutations (e.g., T315I) to evaluate TKI resistance, use CPT code 81170.
  • Do not report 81206 in conjunction with 81403 or 81479 for the same gene analysis.
  • Molecular pathology Tier 1 codes should be used when the specific analyte is listed; 81206 is a Tier 1 code.
  • Ensure documentation supports the medical necessity for frequent monitoring, which is typically every 3 months for CML patients on TKI therapy.

Associated ICD-10 Codes